Compare AMETEK, Inc. (AME) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs GSK plc — how do they compare? AMETEK, Inc. trades at $233.12 (market cap $53.63B), while GSK plc trades at $52.08 (market cap $103.72B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.4%). Which is the better fit depends on your goals.
| AME | GSK | |
|---|---|---|
Market Cap | $53.63B | $103.72B |
Sector | Industrials | Health |
52-Week High | $241.94 | $61.18 |
52-Week Low | $176.44 | $36.20 |
Enterprise Value | $55.33B | $124.33B |
Dividend Yield | 0.58% | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $233.98, up 0.42% today, with a neutral technical signal and strong fundamentals including three consecutive quarterly EPS beats. The company maintains robust profitability with a 20.11% net margin and recently completed the acquisition of First Aviation Services, expanding its aerospace and defense footprint. Cash flow remains positive with $83.95M net inflow in 2025.
Outlook is positive with a $260 consensus price target representing 11% upside, supported by 68.97% analyst buy ratings. Risks include elevated P/E of 35.34 and integration challenges from recent acquisitions. The stock offers growth exposure to industrial technology and aerospace sectors with stable dividend payments.
GSK trades at $52.78, up 0.59% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.27. Revenue grew to $32.67B in 2025, with a net income margin of 17.78%. Recent news includes FDA approval for Utebzi and a $10.6B acquisition of Nuvalent to bolster its oncology pipeline.
GSK presents a balanced outlook with solid profitability and strategic growth in oncology, but faces risks from clinical trial setbacks and competitive pressures. Analyst sentiment is mixed, with 31% buy ratings, suggesting cautious optimism amid pipeline execution uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
